Congress Rallies to Extend Rare Pediatric Disease Priority Review Voucher Program
February 17, 2026Policy & Regulation, Policy, Regulatory, Food and Drug Administration (FDA), Prescription Drugs
On February 3, 2026, the Consolidated Appropriations Act, 2026 (P.L. 119-75) became law and marked an important milestone in the bipartisan congressional effort to reauthorize the rare pediatric disease priority review voucher program. Section 6604 of this law extends the Food and Drug Administration’s (FDA) authority to issue priority review vouchers to encourage treatments for rare pediatric diseases through September 30, 2029.
Search Results
Get the latest FDA and related regulatory developments critical to the life sciences industry delivered to your inbox.
